Patient Perception Study for AL-4943A

Alcon Research47 enrolled

Overview

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Allergic Conjunctivitis

Interventions

AL-4943ADRUG

Once daily topical ocular allergy medication used for 7 days

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of allergic conjunctivitis within last 24 months * Active signs and symptoms of ocular allergies Exclusion Criteria: * Severe or serious ocular condition, ocular surgical intervention, ocular infection

Locations (1)

Alcon Korea Ltd.

Seoul, South Korea

Outcomes

Primary Outcomes

Overall Patient satisfaction

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.